Portfolio / Alveron


Company: ALVERON
Fund: II
Status: Active
Team member: Michel Briejer
Technology: Therapeutics

Alveron Pharma is developing a unique coagulation platform technology with the world’s first cyclodextrin-based anticoagulant reversal drug.

Alveron Pharma's proprietary cyclodextrin-based compounds accelerate, but not initiate, coagulation via a unique mechanism. These compounds can therefore be used as systemic anti-bleeding agents, and our lead program is focused on developing a truly universal anticoagulant reversal agent.